title: Economic implications of early treatment of migraine with sumatriptan tablets.
abstract: BACKGROUND
  Early treatment of migraine with sumatriptan 50 mg and 100 mg, while pain is mild, has been reported to enhance pain-free response 2 hours and 4 hours postdose and sustained pain-free response 2 to 24 hours postdose compared with treatment when pain has become moderate to severe. Early treatment with sumatriptan 50 mg and 100 mg also resulted in less redosing, which translated to a reduction in the mean number of doses used per migraine episode.
  
  
  OBJECTIVE
  We examined the economic implications of early treatment with sumatriptan 50 mg and 100 mg while pain is mild versus treatment when pain has become moderate to severe.
  
  
  METHODS
  Using data from retrospective analyses of a dose-ranging clinical trial of sumatriptan (protocol S2CM09) involving 1003 patients, we estimated the mean cost per treatment success for a hypothetical population of 1000 migraine patients who received treatment with sumatriptan 50-mg or 100-mg tablets early while pain was mild versus treatment when pain had become moderate to severe.
  
  
  RESULTS
  With a conservative estimate of migraine frequency of 1.5 episodes per month, the total cost of early migraine treatment with sumatriptan 50 mg and 100 mg was reduced by $31.68 and $20.16, respectively, per patient per year. The average cost per pain-free treatment success was reduced by 32% to 57% with sumatriptan 50 mg and 100 mg if migraines were treated while pain was mild in intensity versus when pain had become moderate to severe.
  
  
  CONCLUSIONS
  Treatment of migraine with sumatriptan 50-mg and 100-mg tablets is effective regardless of whether pain is mild, moderate, or severe. However, initiating treatment while pain is mild may be more cost-effective than delaying treatment until pain has become moderate to severe.
authors: Headache Care Center, Springfield, Missouri, USA.
authors: R K
authors: RK
authors: Cady
authors: F
authors: F
authors: Sheftell
authors: R B
authors: RB
authors: Lipton
authors: W J
authors: WJ
authors: Kwong
authors: S
authors: S
authors: O'Quinn
mesh_terms: D003363:Cost Control; D016527:Drug Costs; D008881:Migraine Disorders / Q000188:drug therapy / Q000191:economics*; D010146:Pain / Q000188:drug therapy; D012189:Retrospective Studies; D018170:Sumatriptan / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use
chemical_list: D014662:Vasoconstrictor Agents; D018170:Sumatriptan